Xenon Pharmaceuticals Statistics
Total Valuation
XENE has a market cap or net worth of $2.99 billion. The enterprise value is $2.38 billion.
Important Dates
The last earnings date was Monday, August 11, 2025, after market close.
| Earnings Date | Aug 11, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
XENE has 77.11 million shares outstanding. The number of shares has increased by 7.80% in one year.
| Current Share Class | 77.11M |
| Shares Outstanding | 77.11M |
| Shares Change (YoY) | +7.80% |
| Shares Change (QoQ) | +0.34% |
| Owned by Insiders (%) | 0.14% |
| Owned by Institutions (%) | 102.13% |
| Float | 71.60M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 399.31 |
| Forward PS | n/a |
| PB Ratio | 4.71 |
| P/TBV Ratio | 4.72 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 317.15 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 15.14, with a Debt / Equity ratio of 0.01.
| Current Ratio | 15.14 |
| Quick Ratio | 14.79 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -37.65% and return on invested capital (ROIC) is -26.57%.
| Return on Equity (ROE) | -37.65% |
| Return on Assets (ROA) | -25.52% |
| Return on Invested Capital (ROIC) | -26.57% |
| Return on Capital Employed (ROCE) | -49.61% |
| Revenue Per Employee | $22,936 |
| Profits Per Employee | -$850,850 |
| Employee Count | 327 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -4.37M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -0.77% in the last 52 weeks. The beta is 1.16, so XENE's price volatility has been higher than the market average.
| Beta (5Y) | 1.16 |
| 52-Week Price Change | -0.77% |
| 50-Day Moving Average | 33.11 |
| 200-Day Moving Average | 36.10 |
| Relative Strength Index (RSI) | 74.10 |
| Average Volume (20 Days) | 1,069,914 |
Short Selling Information
The latest short interest is 6.97 million, so 9.05% of the outstanding shares have been sold short.
| Short Interest | 6.97M |
| Short Previous Month | 6.51M |
| Short % of Shares Out | 9.05% |
| Short % of Float | 9.74% |
| Short Ratio (days to cover) | 7.99 |
Income Statement
In the last 12 months, XENE had revenue of $7.50 million and -$278.23 million in losses. Loss per share was -$3.54.
| Revenue | 7.50M |
| Gross Profit | -245.13M |
| Operating Income | -318.12M |
| Pretax Income | -199.34M |
| Net Income | -278.23M |
| EBITDA | -315.50M |
| EBIT | -318.12M |
| Loss Per Share | -$3.54 |
Full Income StatementBalance Sheet
The company has $487.55 million in cash and $8.72 million in debt, giving a net cash position of $616.13 million or $7.99 per share.
| Cash & Cash Equivalents | 487.55M |
| Total Debt | 8.72M |
| Net Cash | 616.13M |
| Net Cash Per Share | $7.99 |
| Equity (Book Value) | 633.98M |
| Book Value Per Share | 8.24 |
| Working Capital | 467.21M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$229.94 million and capital expenditures -$1.57 million, giving a free cash flow of -$231.51 million.
| Operating Cash Flow | -229.94M |
| Capital Expenditures | -1.57M |
| Free Cash Flow | -231.51M |
| FCF Per Share | -$3.00 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | -4,241.60% |
| Pretax Margin | -3,767.93% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
XENE does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -7.80% |
| Shareholder Yield | -7.80% |
| Earnings Yield | -9.29% |
| FCF Yield | -7.73% |
Dividend DetailsAnalyst Forecast
The average price target for XENE is $53.20, which is 36.97% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $53.20 |
| Price Target Difference | 36.97% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 10 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | -24.83% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
XENE has an Altman Z-Score of 40.3 and a Piotroski F-Score of 1.
| Altman Z-Score | 40.3 |
| Piotroski F-Score | 1 |
